PLLP抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse kidney tissue, TM4 cell lysates, Primary antibody: P03585(PLLP Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P03585(PLLP Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P03585(PLLP Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

Proteolipid protein (PLP), a major component of myelin in the central nervous system (CNS), plays a critical role in maintaining myelin structure and stability. PLP antibodies target this transmembrane protein and are primarily associated with autoimmune demyelinating disorders. Research has highlighted their relevance in diseases like multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD), where immune-mediated damage to myelin leads to impaired nerve signaling. PLP antibodies are thought to contribute to pathogenesis by binding to myelin sheaths, triggering inflammation, or disrupting axonal integrity. However, their diagnostic specificity remains debated, as PLP reactivity is also observed in healthy individuals or non-inflammatory neurological conditions.

Studies using animal models, such as experimental autoimmune encephalomyelitis (EAE), have demonstrated that PLP peptides can induce autoimmune responses, reinforcing its role as a potential autoantigen. Clinically, detecting PLP antibodies (often alongside other myelin-targeting antibodies like anti-MOG or anti-AQP4) aids in differentiating CNS demyelination subtypes, though their standalone diagnostic value is limited. Recent advances in epitope mapping and antibody characterization aim to refine their pathological significance. Despite ongoing research, PLP antibodies remain a focus in understanding autoimmune neuroinflammation and developing targeted therapies for myelin-related disorders.